GENFIT to receive US$20M milestone from Ipsen as Iqirvo® surpasses US$200M in first year sales on PBC market.
In Lille, France, Cambridge, Massachusetts, United States, and Zurich, Switzerland, on February 12, 2026, GENFIT (Euronext: GNFT), a biopharmaceutical company committed to enhancing the well-being of patients with rare and severe liver ailments, revealed that the exceptional commercial success of Iqirvo® in its initial complete year on the primary biliary cholangitis (PBC) market has led to a significant US$20 million milestone payment from Ipsen as per their licensing deal.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments